Knight Therapeutics Raises FY2026 Sales Guidance from $490.000M-$510.000M to $510.000M-$525.000M vs $499.668M Est.

Benzinga Newsdesk www.benzinga.com Positive 93.8%

Neg 0% Neu 0% Pos 93.8%

Knight Therapeutics (TSX:GUD) raises FY2026 sales outlook from $490.000 million-$510.000 million to $510.000 million-$525.000 million vs $499.668 million estimate.